<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110845">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01769365</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS99-CT7-10</org_study_id>
    <nct_id>NCT01769365</nct_id>
  </id_info>
  <brief_title>Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection</brief_title>
  <official_title>Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To simultaneously compare the efficacies of 7-day triple, 10-day sequential and 7-day
      quadruple therapies for H. pylori infection in Taiwan. Consecutive H. pylori-infected
      patients were randomly assigned to a 7-day standard triple therapy (pantoprazole,
      clarithromycin, and amoxicillin for 7 days), a 10-day sequential therapy (pantoprazole and
      amoxicillin for 5 days, followed by pantoprazole, clarithromycin and metronidazole for a
      further 5 days) or a 7-day quadruple therapy (pantoprazole, clarithromycin, amoxicillin and
      metronidazole for 7 days). The end point is to evaluate the effectiveness of Helicobacter
      pylori eradication rates between three groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the effectiveness of three H. pylori eradication
      regimens: 7-day standard triple therapy (pantoprazole, clarithromycin, and amoxicillin for 7
      days), 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by
      pantoprazole, clarithromycin and metronidazole for a further 5 days) and 7-day quadruple
      therapy (pantoprazole, clarithromycin, amoxicillin and metronidazole for 7 days) in Taiwan.

      A total of 306 subjects are enrolled into this study.

      H. pylori-infected patients are randomized to a 7-day standard triple therapy, a 10-day
      sequential therapy, or a 7-day quadruple therapy. Eradication efficacy is assessed by a
      follow-up endoscopy with rapid urease test and histological examination eight weeks after
      the H. pylori therapy. The eradication rates of three groups will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>eradication rate</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>7-day quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10-day sequential therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7-day standard triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-day quadruple therapy</intervention_name>
    <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days</description>
    <arm_group_label>7-day quadruple therapy</arm_group_label>
    <other_name>Pantoprazole, amoxicillin, clarithromycin, metronidazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-day sequential therapy</intervention_name>
    <description>pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days</description>
    <arm_group_label>10-day sequential therapy</arm_group_label>
    <other_name>sequential group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-day standard triple therapy</intervention_name>
    <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days</description>
    <arm_group_label>7-day standard triple therapy</arm_group_label>
    <other_name>pantoprazole, clarithromycin, amoxicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive H. pylori-infected outpatients, at least 20 years of age, with
             endoscopically proven peptic ulcer diseases or gastritis

        Exclusion Criteria:

          -  previous H. pylori-eradication therapy

          -  ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 weeks

          -  patients with allergic history to the medications used

          -  patients with previous gastric surgery

          -  the coexistence of serious concomitant illness (for example, decompensated liver
             cirrhosis, uremia)

          -  pregnant women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ping-I Hsu, MD</last_name>
    <phone>+886-7-342-2121</phone>
    <phone_ext>8233</phone_ext>
    <email>williamhsup@yahoo.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeng-Yih Wu, MD</last_name>
    <phone>+886-7-3121101</phone>
    <email>joywu@cc.kmu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung city</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping-I Hsu, MD, PHD</last_name>
      <phone>+886-7-342-2121</phone>
      <phone_ext>2075</phone_ext>
      <email>williamhsup@yahoo.com.tw</email>
    </contact>
    <contact_backup>
      <last_name>Kwok-Hung Lai, MD</last_name>
      <phone>+886-7-3422121</phone>
      <phone_ext>2075</phone_ext>
      <email>khlai@isca.vghks.gov.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Ping-I Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 14, 2013</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Ping-I (William) Hsu, M.D.</investigator_full_name>
    <investigator_title>Chief of Division of Gastroenterology; Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori infection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
